Dr. Rachna Shroff, MD
Hematology & Oncology (Hematology & Oncology Physician)
3838 N Campbell Ave Unit 10
Tucson, AZ 85719
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 105
Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Jefferson Medical College of Thomas Jefferson University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license M7626 (first issued 2007; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 295
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 162 | 72 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Tucson, AZ | 67 |
| Ondansetron Odt (ondansetron) Other prescribers in Tucson, AZ | 55 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Tucson, AZ | 44 |
| Creon (lipase/protease/amylase) Other prescribers in Tucson, AZ | 29 |
| Oxycodone Hcl Other prescribers in Tucson, AZ | 27 |
| Duloxetine Hcl Other prescribers in Tucson, AZ | 26 |
| Eliquis (apixaban) Other prescribers in Tucson, AZ | 15 |
| Levothyroxine Sodium Other prescribers in Tucson, AZ | 13 |
| Dexamethasone Other prescribers in Tucson, AZ | 13 |
| Potassium Chloride Other prescribers in Tucson, AZ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 26 payments worth $21,046 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $10,932 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $7,641 |
| AstraZeneca UK Limited | $1,271 |
| Boston Scientific Corporation | $375 |
| Novocure Inc. | $368 |
| Amgen Inc. | $143 |
| Incyte Corporation | $125 |
| Daiichi Sankyo Inc. | $124 |
| Consulting Fee | $9,805 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,370 |
| Travel and Lodging | $1,952 |
| Grant | $1,800 |
| Food and Beverage | $1,118 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc May 9, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde; Tazverik · Oncology | $6,370 |
| AstraZeneca Pharmaceuticals LP Jan 27, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $5,740 |
| AstraZeneca Pharmaceuticals LP Jan 23, 2025 | GrantCompany’s descriptionOther Support | $1,800 |
| AstraZeneca Pharmaceuticals LP May 9, 2025 | Consulting Fee IMFINZI · Oncology | $1,640 |
| AstraZeneca UK Limited Nov 14, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,230 |
| AstraZeneca Pharmaceuticals LP Nov 5, 2025 | Consulting Fee | $820 |
| Ipsen Biopharmaceuticals, Inc May 9, 2025 | Travel and Lodging Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind | $726 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Travel and Lodging IMFINZI · Oncology · travel to San Francisco, CA Company’s descriptionResearch Related Service | $429 |
| Boston Scientific Corporation Jul 31, 2025 | Consulting Fee TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) · TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)_PI | $375 |
| Novocure Inc. Nov 8, 2025 | Travel and Lodging travel to Dallas, TX | $368 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Nov 14, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,230 |
| Novocure Inc. Nov 8, 2025 | Travel and Lodging travel to Dallas, TX | $368 |
| AstraZeneca Pharmaceuticals LP Nov 5, 2025 | Consulting Fee | $820 |
| Boston Scientific Corporation Jul 31, 2025 | Consulting Fee TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) · TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)_PI | $375 |
| Ipsen Biopharmaceuticals, Inc May 9, 2025 | Compensation for services other than consulting (speaking, faculty) Onivyde; Tazverik · Oncology | $6,370 |
| AstraZeneca Pharmaceuticals LP May 9, 2025 | Consulting Fee IMFINZI · Oncology | $1,640 |
| Ipsen Biopharmaceuticals, Inc May 9, 2025 | Travel and Lodging Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind | $726 |
| Ipsen Biopharmaceuticals, Inc May 9, 2025 | Travel and Lodging Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind | $344 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Travel and Lodging IMFINZI · Oncology · travel to San Francisco, CA Company’s descriptionResearch Related Service | $429 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Travel and Lodging IMFINZI · Oncology · travel to San Francisco, CA Company’s descriptionResearch Related Service | $86.91 |
| AstraZeneca Pharmaceuticals LP Jan 27, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $5,740 |
| AstraZeneca Pharmaceuticals LP Jan 23, 2025 | GrantCompany’s descriptionOther Support | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 9 companies. The companies reported $128,087 in research payments for these studies, mostly to the institutions running them.
- A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated locallyadvanced unresectable or metastatic solid tumors driven by HER2 alterations
Pfizer Inc. - EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
Novocure Inc. - A phase III randomized control trial of gemcitbaine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Celgene Corporation - Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company · Active, not recruiting · NCT04521686 - A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response …
Merck Sharp & Dohme LLC - Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Exelixis Inc. - Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors
Boehringer Ingelheim Pharmaceuticals, Inc. - Study name not reported
Organon Llc - SRF388-201
Coherus Oncology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.